Table 3.

Combination and Dual Targeting with MNK Inhibitors in Preclinical Studies

	MNK Inhibitor or MNK Target	Other Target in the Study	Inhibitor of Other Target in the Study	Leukemia Type	Combination Effects	Reference
Combination	Niclosamide (Erk/Mnk1/eIF4E)	BCR::ABL1	Dasatinib	CML	Antiproliferative Proapoptotic	[89]
Combination	CGP57380	BCR::ABL1	Imatinib	CML	Antiproliferative Proapoptotic Cell cycle arrest Impaired polysome assembly	[88]
Combination	eFT508	BCL2	Venetoclax	AML	↓ Viability ↓ Colony formation	[9]
Combination	MNKI-4, MNKI-57	mTORC1	Rapamycin	CML	Antiproliferative Proapoptotic Cell cycle arrest	[93]
Combination	CGP57380	mTORC1	Rapamycin	AML	↓ Colony formation	[85]
Combination	Cercosporamide	mTORC1	Rapamycin	AML	↓ Colony formation	[77]
Combination	SEL201	mTORC1	Rapamycin	AML	↓ Viability ↓ Colony formation	[79]
Combination	CGP57380	mTORC1	Everolimus	T-ALL	↓ Viability Proapoptotic	[92]
Combination	SEL201	Hypomethylating agent	5-Azacytidine	AML	↓ Viability ↓ Colony formation Proapoptotic	[79]
Combination	Cercosporamide	Chemotherapy	Cytarabine	AML	↓ Colony formation ↓ Tumor volume	[77]
Combination	CGP57380	Chemotherapy	Cytarabine	AML	↓ Colony formation Proapoptotic	[85]
Combination	MNKI-8e	Chemotherapy	Cytarabine	AML	↓ Viability Proapoptotic	[86]
Dual	MNK1&2	BTK		AML, CLL	Antiproliferative Proapoptotic Cell cycle arrest	[96]
Dual	MNK1&2	PIM1, 2, & 3		AML	Antiproliferative Proapoptotic Cell cycle arrest ↓ Tumor volume	[7]
Dual	MNK2	PIM2		AML potential	Only in silico analysis	[95]
Dual	Reduced p-eIF4E	PIM1, 2, & 3		AML, CML	Antiproliferative Proapoptotic	[76]
Dual	MNK2	FLT3		AML	↓ Viability Cell cycle arrest	[8]
Dual	MNK1&2	BCR::ABL1		CML	Antiproliferative ↓ Tumor volume	[97]